Biohaven’s stock jumps 12% after saying its migraine drug had $93 million in sales in Q2

Shares of Biohaven Pharmaceutical Holding Co. Ltd. BHVN, +12.73% were up 12.1% in premarket trading on Wednesday after the company said its new migraine treatment brought in $93 million in sales in the second quarter of 2021. The drug, Nurtec Odt, can be used to treat and prevent migraines. It has generated a total of $200 million in net revenue since launching in the U.S. in March 2020. Biohaven’s stock is up 15.3% for the year, while the broader S&P 500 SPX, +0.29% has gained 15.6%.

View Article Origin Here